MDX010
Showing 1 - 25 of 196
Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma Trial (Nivolumab, Ipilimumab, Surgical Procedure)
Not yet recruiting
- Pleural Biphasic Mesothelioma
- Pleural Sarcomatoid Mesothelioma
- Nivolumab
- +5 more
- (no location specified)
Dec 9, 2022
Squamous Cell Carcinoma of the Head and Neck Trial in Portland (Intratumoral Ipilimumab)
Active, not recruiting
- Squamous Cell Carcinoma of the Head and Neck
- Intratumoral Ipilimumab
-
Portland, OregonPortland Providence Medical Center
Jan 8, 2023
Melanoma Trial in Boston (Bevacizumab Plus Ipilimumab Cohort 1, Bevacizumab Plus Ipilimumab Cohort 2, Bevacizumab Plus
Active, not recruiting
- Melanoma
- Bevacizumab Plus Ipilimumab Cohort 1
- +3 more
-
Boston, Massachusetts
- +2 more
Nov 8, 2021
Gastrointestinal Stromal Tumor Trial in Los Angeles (Ipilimumab, Laboratory Biomarker Analysis, Nivolumab)
Completed
- Gastrointestinal Stromal Tumor
- Ipilimumab
- +2 more
-
Los Angeles, CaliforniaRachel Andes
Aug 15, 2022
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 Trial
Recruiting
- Advanced Clear Cell Renal Cell Carcinoma
- +3 more
- Cabozantinib
- +2 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Dec 2, 2022
Kidney Medullary Carcinoma, Loss of INI 1 Protein Expression, Stage III Renal Cell Cancer AJCC v8 Trial in Houston (Ipilimumab,
Active, not recruiting
- Kidney Medullary Carcinoma
- +3 more
- Ipilimumab
- Nivolumab
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Larynx, Lip, Oral Cavity and Pharynx Trial in Philadelphia (Nivolumab, Ipilimumab, Simultaneous-Integrated Boost
Completed
- Larynx
- Lip, Oral Cavity and Pharynx
- Nivolumab
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Nov 16, 2022
Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma, Uterine Corpus Leiomyosarcoma Trial in Boston (Ipilimumab, Laboratory
Active, not recruiting
- Metastatic Leiomyosarcoma
- +2 more
- Ipilimumab
- +2 more
-
Boston, Massachusetts
- +1 more
Jun 28, 2022
Soft Tissue Sarcoma Trial in Stanford (Ipilimumab, Cryoablation, Nivolumab)
Active, not recruiting
- Soft Tissue Sarcoma
- Ipilimumab
- +2 more
-
Stanford, CaliforniaStanford Medical Center
Feb 2, 2022
Metastatic Extraskeletal Myxoid Chondrosarcoma, Metastatic Leiomyosarcoma, Metastatic Liposarcoma Trial (procedure, drug,
Not yet recruiting
- Metastatic Extraskeletal Myxoid Chondrosarcoma
- +3 more
- Biopsy
- +6 more
- (no location specified)
Apr 25, 2023
Metastatic Malignant Tumor in the Brain, Stage IV NSCLC AJCC v7 Trial in Houston (procedure, biological, other, radiation)
Recruiting
- Metastatic Malignant Neoplasm in the Brain
- Stage IV Non-Small Cell Lung Cancer AJCC v7
- Cognitive Assessment
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Dec 12, 2022
Squamous Cell Carcinoma of the Head and Neck Trial in Pittsburgh (Nivolumab+Relatlimab, Nivolumab+Ipilimumab)
Recruiting
- Squamous Cell Carcinoma of the Head and Neck
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Jul 13, 2022
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Trial
Not yet recruiting
- Metastatic Nasopharyngeal Carcinoma
- +2 more
- Biospecimen Collection
- +5 more
- (no location specified)
Jun 13, 2023
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Melanoma Trial in Houston
Recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +3 more
- Ipilimumab
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Hematopoietic and Lymphoid Cell Tumor, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in
Not yet recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +5 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 10, 2022
Renal Cell Carcinoma Trial in Houston (Ipilimumab, Nivolumab, Ciforadenant)
Not yet recruiting
- Renal Cell Carcinoma
- Ipilimumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 11, 2022
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Recruiting
- Acute Bilineal Leukemia
- +8 more
- Azacitidine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 24, 2023
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 Trial in Duarte
Recruiting
- Clear Cell Renal Cell Carcinoma
- +3 more
- Biospecimen Collection
- +6 more
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 19, 2023
Melanoma, Unresectable Melanoma Trial in Los Angeles, Boston, New York (Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab)
Not yet recruiting
- Melanoma
- Unresectable Melanoma
- Sarilumab
- +2 more
-
Los Angeles, California
- +3 more
Aug 4, 2022
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in
Recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +3 more
- Ipilimumab
- Nivolumab
-
Rochester, MinnesotaMayo Clinic in Rochester
May 6, 2022
Advanced Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma Trial in Duarte (Clostridium
Active, not recruiting
- Advanced Renal Cell Carcinoma
- +5 more
- Clostridium butyricum CBM 588 Probiotic Strain
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Oct 12, 2022
Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Tumor in the Brain Trial in
Recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +6 more
- Ipilimumab
- +4 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Dec 12, 2022
Melanoma Trial in Houston (ABI-007, Ipilimumab, Phone Call)
Completed
- Melanoma
- ABI-007
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jan 12, 2022
Advanced Malignant Solid Tumor, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8 Trial
Recruiting
- Advanced Malignant Solid Neoplasm
- +8 more
- Imatinib Mesylate
- Ipilimumab
-
Houston, TexasM D Anderson Cancer Center
Aug 1, 2022